-
Legislators across the nation are grappling with the contentious issue of whether pharmacists have the right to refuse to fill birth control prescriptions on moral or religious grounds and in turn the obligation of pharmacies to meet the needs of consumers seeking to avoid unintended pregnancies if and when pharmacists refuse.
-
Teens may be up to speed when it comes to movies, music, and sports, but when it comes to knowledge of prevention and treatment of sexually transmitted diseases (STDs), they are falling behind, a new national report reveals.
-
The company responsible for developing the Essure non-incisional permanent birth control procedure is seeking approval from the Food and Drug Administration (FDA) to extend effectiveness data on the Essure product labeling.
-
New data from a long-term cohort study comparing bone mineral densities (BMD) in adult users and nonusers of the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City) indicate that while bone mineral density declines in current DMPA users, it is followed by substantial recovery after discontinuation.
-
Is use of depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City) linked to risk of toxic shock syndrome? Contraceptive Technology Update Editorial Advisory Board member Felicia Stewart, MD, adjunct professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California San Francisco and co-director of the Center for Reproductive Health Research & Policy, tackles this question.
-
Reaching teens with up-to-date information is an important part of providing family planning and sexually transmitted disease (STD) counseling. Consider these web sites:
-
Rewind to 1998: The Centers for Disease Control and Prevention (CDC) launches its plan to eliminate syphilis in the United States, with the goals of reducing the total number of primary and secondary syphilis cases to 1,000 or fewer 0.4 cases per 100,000 people and increasing the number of syphilis-free counties to 90% by 2005.
-
Ready to update your knowledge on family planning issues and network with fellow clinicians? Take advantage of upcoming fall conferences, all aimed at family planning providers.
-
This prospective study recruited 20 healthy, HIV-uninfected subjects to receive a 6-week course of either stavudine (d4T) plus lamivudine (3TC) or zidovudine (ZDV) plus lamivudine.
-
The Advisory Committee on Immunization Practices (ACIP) has recommended that the new acellular pertussis vaccine be routinely administered to all 11 and 12-year-olds as part of routine preventative care.
